Axsome Therapeutics Reaches Agreement to Dismiss Sunosi® (Solriamfetol) Patent Litigation with Sandoz Inc.GlobeNewsWire • 08/21/24
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmGlobeNewsWire • 08/11/24
Does Axsome (AXSM) Have the Potential to Rally 48.44% as Wall Street Analysts Expect?Zacks Investment Research • 08/05/24
Axsome Plunges On Wide Losses, But Its Biggest Moneymaker Tacks On 135% GrowthInvestors Business Daily • 08/05/24
Axsome Therapeutics (AXSM) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research • 08/05/24
Axsome Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business UpdateGlobeNewsWire • 08/05/24
Axsome Therapeutics' CNS Portfolio Poised for Major Growth - Analyst Predicts Strong FutureBenzinga • 07/22/24
Wall Street Analysts Predict a 49.36% Upside in Axsome (AXSM): Here's What You Should KnowZacks Investment Research • 07/18/24
Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Unichem LaboratoriesGlobeNewsWire • 06/05/24
Axsome Therapeutics Joins the American Migraine Foundation to Highlight Unmet Treatment Needs During Migraine & Headache Awareness MonthGlobeNewsWire • 06/04/24
Axsome Therapeutics Highlights Data on Solriamfetol Demonstrating Improvement in Cognitive Function in Patients with Obstructive Sleep Apnea or Narcolepsy at SLEEP 2024GlobeNewsWire • 05/29/24